Triamcinolone acetonide and Emend drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Triamcinolone acetonide (triamcinolone acetonide) and Emend (aprepitant). Common drug interactions include infusion related reaction among females and constipation among males.

The phase IV clinical study analyzes what interactions people have when they take Triamcinolone acetonide and Emend. It is created by eHealthMe based on reports of 91 people who take the same drugs from the FDA, and is updated regularly.

What is Triamcinolone acetonide?

Triamcinolone acetonide has active ingredients of triamcinolone acetonide. It is often used in eczema. eHealthMe is studying from 19,594 Triamcinolone acetonide users. Check the latest studies of Triamcinolone acetonide.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.



On Jul, 10, 2026

91 people who take Triamcinolone acetonide and Emend together, and have interactions are studied.

Triamcinolone acetonide and Emend drug interactions.

What are the common drug interactions of Triamcinolone Acetonide and Emend, by gender? *:

female:

  1. Infusion related reaction
  2. Mobility decreased (ability to move is reduced)
  3. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  4. Irritable bowel syndrome
  5. Pemphigus (any of several acute or chronic skin diseases characterized by groups of itching blisters)
  6. Pyrexia (fever)
  7. Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints)
  8. Synovitis (inflammation of the synovial membrane)
  9. Vomiting
  10. Folliculitis (infection of hair root)

male:

  1. Constipation
  2. Pneumonia

What are the common drug interactions of Triamcinolone Acetonide and Emend, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Pneumonia
  2. Sepsis (a severe blood infection that can lead to organ failure and death)
  3. Thrombocytopenia (decrease of platelets in blood)
  4. Febrile neutropenia (fever with reduced white blood cells)

30-39:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

40-49:

  1. Confusional state
  2. General physical health deterioration (weak health status)
  3. Duodenal ulcer perforation (untreated ulcer can burn through the wall of the stomach)
  4. Infusion related reaction
  5. Mobility decreased (ability to move is reduced)
  6. Fatigue (feeling of tiredness)
  7. Glossodynia (a burning or painful sensation in the tongue)
  8. Sleep disorder
  9. Irritable bowel syndrome
  10. Joint range of motion decreased (disease of joint movement)

50-59:

n/a

60+:

  1. Arthralgia (joint pain)
  2. Bone pain
  3. Fatigue (feeling of tiredness)
  4. Neutropenia (an abnormally low number of neutrophils)
  5. White blood cell count decreased
  6. Alopecia (absence of hair from areas of the body)
  7. Constipation
  8. Hair colour changes
  9. Hair disorder

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 82 people, 90.11%
  2. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 74 people, 81.32%
  3. Arthritis (form of joint disorder that involves inflammation of one or more joints): 59 people, 64.84%
  4. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 57 people, 62.64%
  5. Psoriasis (immune-mediated disease that affects the skin): 38 people, 41.76%
  6. Inflammation: 30 people, 32.97%
  7. Synovitis (inflammation of the synovial membrane): 29 people, 31.87%
  8. Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 29 people, 31.87%
  9. Fever: 29 people, 31.87%
  10. Pemphigus (any of several acute or chronic skin diseases characterized by groups of itching blisters): 28 people, 30.77%

* Approximation only. Some reports may have incomplete information.

Do you take Triamcinolone acetonide and Emend?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Triamcinolone acetonide and Emend:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Triamcinolone acetonide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Emend:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Triamcinolone acetonide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Emend and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on triamcinolone acetonide and aprepitant (the active ingredients of Triamcinolone acetonide and Emend, respectively), and Triamcinolone acetonide and Emend (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: